Mueller-Eckhardt C, Kiefel V
Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig-University, Giessen, Federal Republic of Germany.
Blut. 1988 Oct;57(4):163-7. doi: 10.1007/BF00319544.
Therapy for post-transfusion purpura (PTP) is controversial. We have evaluated the effect of high-dose IgG (HDIgG) in 11 PTP cases investigated in our institution and summarized the clinical data of 8 additional cases reported in the literature. Two of these 19 cases had to be eliminated from the analysis (1 patient received a total dose of less than 30 g of IgG; 1 patient died 2 days after starting HDIgG therapy from congestive heart failure). Out of a total of 17 cases, 16 had good or excellent response reaching normal platelet values within few days; only one failure was observed. Five patients relapsed, but attained complete remission after a second course (dose) of IgG. Total doses per course ranged between 52 and 180 g of IgG. Five different IgG preparations were used and seemed similarly effective. No adverse reactions were observed. We conclude that HDIgG is the treatment of choice for PTP.
输血后紫癜（PTP）的治疗存在争议。我们评估了大剂量免疫球蛋白（HDIgG）对本院调查的11例PTP患者的疗效，并总结了文献报道的另外8例患者的临床资料。这19例患者中有2例需排除在分析之外（1例患者接受的免疫球蛋白总剂量少于30g；1例患者在开始HDIgG治疗2天后死于充血性心力衰竭）。总共17例患者中，16例反应良好或极佳，在数天内血小板值恢复正常；仅观察到1例治疗失败。5例患者复发，但在第二疗程（剂量）免疫球蛋白治疗后完全缓解。每个疗程的总剂量在52至180g免疫球蛋白之间。使用了5种不同的免疫球蛋白制剂，似乎疗效相似。未观察到不良反应。我们得出结论，HDIgG是PTP的首选治疗方法。
